Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain

eLife

Volumn 4, Issue NOVEMBER2015, 2015, Pages

  Brumshtein, Boris ^a,b,c   Esswein, Shannon R ^a,b,c   Salwinski, Lukasz ^a,b,c   Phillips, Martin L ^b,c   Ly, Alan T ^a,b,c   Cascio, Duilio ^a,b,c   Sawaya, Michael R ^a,b,c   Eisenberg, David S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 NAPHTHOQUINONE; 1,4 NAPHTHOQUINONE; 6 CARBOXYFLUORESCEIN; AMYLOID; APOMORPHINE; BASIC BLUE 12; DIETHYLSTILBESTROL; DIMENHYDRINATE; DOPAMINE; DOXYCYCLINE; EOSIN; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; JUGLONE; METHOXY 2 NAPHTHYL PROPIONIC ACID; METHYLENE BLUE; PHENOLSULFONPHTHALEIN; PHENYLALANINE; PROTEIN INHIBITOR; QUINONE DERIVATIVE; RECOMBINANT PROTEIN; RHODAMINE 6G; SALAZOSULFAPYRIDINE; SULINDAC; TAMOXIFEN; TETRACYCLINE; THIOFLAVINE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIGAND;

AMYLOIDOSIS; ARTICLE; CONCENTRATION (PARAMETERS); CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; EQUILIBRIUM DIALYSIS; FLUORESCENCE SPECTROSCOPY; LIGAND BINDING; PROTEIN SYNTHESIS INHIBITION; ULTRACENTRIFUGATION; X RAY DIFFRACTION;

AMYLOID; IMMUNOGLOBULIN LIGHT CHAINS; LIGANDS;

EID: 84957927035     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.10935     Document Type: Article

References (55)

1. Baden EM, Randles EG, Aboagye AK, Thompson JR, Ramirez-Alvarado M. 2008. Structural insights into the role of mutations in amyloidogenesis. Journal of Biological Chemistry 283:30950-30956. doi: 10.1074/jbc.M804822200.
2. Baures PW, Peterson SA, Kelly JW. 1998. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorganic & Medicinal Chemistry 6:1389-1401.
3. Bellotti V, Mangione P, Merlini G. 2000. Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. Journal of Structural Biology 130:280-289. doi: 10.1006/jsbi.2000.4248.
4. Bernier GM, Putnam FW. 1963. Monomer-Dimer Forms of Bence Jones Proteins. Nature 200:223-225. doi: 10.1038/200223b0.
5. Bodi K, Prokaeva T, Spencer B, Eberhard M, Connors LH, Seldin DC. 2009. AL-base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid 16:1-8. doi: 10.1080/ 13506120802676781.
6. Bork P, Holm L, Sander C. 1994. The immunoglobulin fold. structural classification, sequence patterns and common core. Journal of Molecular Biology 242:309-320. doi: 10.1006/jmbi.1994.1582.
7. Brumshtein B, Esswein SR, Landau M, Ryan CM, Whitelegge JP, Phillips ML, Cascio D, Sawaya MR, Eisenberg DS. 2014. Formation of amyloid fibers by monomeric light chain variable domains. Journal of Biological Chemistry 289:27513-27525. doi: 10.1074/jbc.M114.585638.
8. Bulawa CE, Connelly S, DeVit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R. 2012. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America 109:9629-9634. doi: 10.1073/pnas.1121005109.
9. Buxbaum J. 1986. Aberrant immunoglobulin synthesis in light chain amyloidosis. free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. Journal of Clinical Investigation 78:798-806. doi: 10.1172/JCI112643.
10. Buxbaum J. 1992. Mechanisms of disease: monoclonal immunoglobulin deposition. amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematology/oncology Clinics of North America 6:323-346.
11. Cohn E, Edsall J. 1943. Density and apparent specific volume of proteins. Proteins, Amino Acids and Peptides as Ions and Dipolar Ions. New York: Reinhold Publishing Corporation.
12. Colman PM, Schramm HJ, Guss JM. 1977. Crystal and molecular structure of the dimer of variable domains of the bence-jones protein ROY. Journal of Molecular Biology 116:73-79. doi: 10.1016/0022-2836(77)90119-X.
13. Dahlin DC, Dockerty MB. 1950. Amyloid and myeloma. The American Journal of Pathology 26:581-593.
14. DeLano W, Schrödinger, Llc. The PyMol Molecular Graphics System. Version 1.7.4. 2002.
15. Edmundson AB, Wood MK, Schiffer M, Hardman KD, Ainsworth CF. 1969. A crystallographic investigation of the mcg myeloma protein. ANL-7635. ANL:283-285.
16. Edmundson AB, Ely KR, Abola EE, Schiffer M, Panagiotopoulos N, Deutsch HF. 1976. Conformational isomerism, rotational allomerism, and divergent evolution in immunoglobulin light chains. Federation Proceedings 35: 2119-2123.
17. Edmundson AB, Ely KR, Herron JN. 1984. A search for site-filling ligands in the mcg bence-jones dimer: crystal binding studies of fluorescent compounds. Molecular Immunology 21:561-576.
18. Edmundson AB, Harris DL, Fan Z-C, Guddat LW, Schley BT, Hanson BL, Tribbick G, Geysen HM. 1993. Principles and pitfalls in designing site-directed peptide ligands. Proteins 16:246-267. doi: 10.1002/prot.340160304.
19. Ely KR, Herron JN, Harker M, Edmundson AB. 1989. Three-dimensional structure of a light chain dimer crystallized in water. Journal of Molecular Biology 210:601-615. doi: 10.1016/0022-2836(89)90135-6.
20. Falk RH, Comenzo RL, Skinner M. 1997. The systemic amyloidoses. The New England Journal of Medicine 337: 898-909. doi: 10.1056/NEJM199709253371306.
21. Fink AL. 1998. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Folding & Design 3:R9-R23. doi: 10.1016/S1359-0278(98)00002-9.
22. Firca JR, Ely KR, Kremser P, Westholm FA, Dorrington KJ, Edmundson AB. 1978. Interconversion of conformational isomers of light chains in the mcg immunoglobulins. Biochemistry 17:148-158. doi: 10.1021/bi00594a022.
23. Geddes AJ, Parker KD, Atkins EDT, Beighton E. 1968. “cross-b” conformation in proteins. Journal of Molecular Biology 32:343-358. doi: 10.1016/0022-2836(68)90014-4.
24. Glenner GG, Harbaugh J, Ohms JI, Harada M, Cuatrecasas P. 1970. An amyloid protein: the amino-terminal variable fragment of an immunoglobulin light chain. Biochemical and Biophysical Research Communications 41: 1287-1289. doi: 10.1016/0006-291X(70)90227-5.
25. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. 1971. Creation of "amyloid" fibrils from bence jones proteins in vitro. Science 174:712-714. doi: 10.1126/science.174.4010.712.
26. Glenner GG. 1973. Immunoglobulin and amyloid fibril proteins. British Journal of Haematology 24:533-537. doi: 10.1111/j.1365-2141.1973.tb01679.x.
27. Hobbs JR. 1973. An ABC of amyloid. Proceedings of the Royal Society of Medicine 66:705-710.
28. Hurle M, Helms L, Li L, Chan W, Wetzel R. 1994. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proceedings of the National Academy of Sciences of the United States of America 91:5446-5450. doi: 10.1073/pnas.91.12.5446.
29. Kabsch W. 2010. Xds. Acta Crystallographica Section D Biological Crystallography 66:125-132. doi: 10.1107/ S0907444909047337.
30. Khurana R, Gillespie JR, Talapatra A, Minert LJ, Ionescu-Zanetti C, Millett I, Fink AL. 2001. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40: 3525-3535. doi: 10.1021/bi001782b.
31. Kishida F, Azuma T, Hamaguchi K. 1975. A type kappa bence jones protein containing a cysteinyl residue in the variable region. Journal of Biochemistry 77:481-491.
32. Kyle RA. 2001. Amyloidosis: a convoluted story. British Journal of Haematology 114:529-538.
33. Kyle RA. 2011. Amyloidosis: a brief history. Amyloid 18 Suppl 1:6-7. doi: 10.3109/13506129.2011.574354001.
34. Laue T, Shah B, Ridgeway T, Pelletier S. 1992. Computer-Aided Interpretation of Analytical Sedimentation Data for Proteins. Analytical Ultracentrifugation in Biochemistry and Polymer Science. Cambridge, Great Britain: The Royal Society of Chemistry.
35. Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Theberge R, Connors LH, Bellotti V, Seldin DC, Merlini G, Skinner M, Costello CE. 2008. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Molecular & Cellular Proteomics 7:1570-1583. doi: 10.1074/mcp.M700545-MCP200.
36. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. 2014. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Research 42:D1091-D1097. doi: 10.1093/nar/gkt1068.
37. Makino D, Henschen-Edman A, Larson S, McPherson A. 2007. Bence jones kwr protein structures determined by x-ray crystallography. Acta Crystallographica Section D Biological Crystallography 63:780-792. doi: 10.1107/S0907444907021981.
38. Marchalonis JJ, Schluter SF. 1989. Evolution of variable and constant domains and joining segments of rearranging immunoglobulins. Faseb Journal 3:2469-2479.
39. Miroy G, Lai Z, Lashuel H, Peterson S, Strang C, Kelly J. 1996. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proceedings of the National Academy of Sciences of the United States of America 93: 15051-15056. doi: 10.1073/pnas.93.26.15051.
40. Murshudov G, Vagin A, Dodson E. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallographica Section D Biological Crystallography 53:240-255. doi: 10.1107/S0907444996012255.
41. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross- beta spine of amyloid-like fibrils. Nature 435:773-778. doi: 10.1038/nature03680.
42. Olsen KE, Sletten K, Westermark P. 1998. Fragments of the constant region of immunoglobulin light chains are constituents of Al-amyloid proteins. Biochemical and Biophysical Research Communications 251:642-647. doi: 10.1006/bbrc.1998.9508.
43. Pelaez-Aguilar AE, Rivillas-Acevedo L, French-Pacheco L, Valdes-Garcia G, Maya-Martinez R, Pastor N, Amero C. 2015. Inhibition of light chain 6aJL2-R24G amyloid fiber formation associated with light chain amyloidosis. Biochemistry 54:4978-4986. doi: 10.1021/acs.biochem.5b00288.
44. Qin Z, Hu D, Zhu M, Fink AL. 2007. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry 46:3521-3531. doi: 10.1021/bi061716v.
45. Sakano H, Hüppi K, Heinrich G, Tonegawa S. 1979. Sequences at the somatic recombination sites of immunoglobulin light-chain genes. Nature 280:288-294. doi: 10.1038/280288a0.
46. Scatchard G. 1949. The attractions of proteins for small molecules and ions. Annals of the New York Academy of Sciences 51:660-672. doi: 10.1111/j.1749-6632.1949.tb27297.x.
47. Sipe JD, Cohen AS. 2000. Review: history of the amyloid fibril. Journal of Structural Biology 130:88-98. doi: 10.1006/jsbi.2000.4221.
48. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. 2014. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21:221-224. doi: 10.3109/13506129.2014.964858.
49. Solomon A, Weiss DT. 1995. Structural and functional properties of human lambda-light-chain variable-region subgroups. Clinical and Diagnostic Laboratory Immunology 2:387-394.
50. Spitzer R, McDonald H. 1956. Comparison of the binding properties of bovine plasma albumin and polyvinylpyrrolidone. Clinica Chimica Acta 1:545-556. doi: 10.1016/0009-8981(56)90042-0.
51. Terzyan SS, Bourne CR, Ramsland PA, Bourne PC, Edmundson AB. 2003. Comparison of the three-dimensional structures of a human bence-jones dimer crystallized on earth and aboard US space shuttle mission STS-95. Journal of Molecular Recognition 16:83-90. doi: 10.1002/jmr.610.
52. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. 2009. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114: 4957-4959. doi: 10.1182/blood-2009-07-230722.
53. Wall J, Murphy CL, Solomon A. 1999. In vitro immunoglobulin light chain fibrillogenesis. Methods in Enzymology 309:204-217. doi: 10.1016/S0076-6879(99)09016-3.
54. Waters NJ, Jones R, Williams G, Sohal B. 2008. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. Journal of Pharmaceutical Sciences 97:4586-4595. doi: 10.1002/jps.21317.
55. Wetzel R. 1994. Mutations and off-pathway aggregation of proteins. Trends in Biotechnology 12:193-198. doi: 10.1016/0167-7799(94)90082-5.